Over the past year and a half, two alumni of our Oakland and Baltimore chapters, Louise Lassalle and Yann Huon de Kermadec, have been working to establish a French chapter of the Open Insulin Foundation. (See the official announcement.) Here is their account of the process.
With apologies for a long hiatus from regular public communications, we have much news to share as the holidays approach and we reflect, celebrate, and prepare for the new year. We remain actively seized on the specific mission of Open Insulin, which is to make open source technology to make insulin and organize local production under accountable ownership and governance. Here are the highlights regarding the current state of our work.
Three pharmaceutical companies control the patent rights for the majority of insulin products on the market. These companies have over the past decade raised the price of insulin egregiously. As a result, many diabetics and their families are struggling to afford this life-saving medicine and, in some cases, taking desperate actions to get the medicine their life depends on.
Introduction It’s been a busy past few months at Open Insulin! We’ve had significant progress on all fronts, especially in moving the engineering of our organisms forward towards the point where production pilots can be started in collaboration with external partners. Details below.
Open Insulin is working to make an open source protein purification system (FPLC), which is a key piece of equipment for manufacturing insulin, and one that is currently very expensive. Avery McLain spoke with Vadim Kimlaychuk, one of the lead engineers working on the FPLC project, about his work, as the first installment in a series of interviews we have planned with project participants and stakeholders.